EARLY, INTERMEDIATE, AND LATE RETINAL BIOMARKERS FOR ASSESSING NEUROPROTECTION FOLLOWING ACUTE OPTIC NEURITIS: INSIGHT AND EXPLORATION OF RENEW, OPICINUMAB IN AON PHASE 2 CLINICAL TRIAL
$999,741FY2025Defense Health AgencyDOD
The Johns Hopkins University